Ind-Swift Laboratories (BOM:532305) ROCE % : -0.38% (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Ind-Swift Laboratories ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ind-Swift Laboratories's annualized ROCE % for the quarter that ended in Dec. 2024 was -0.38%.

Ind-Swift Laboratories ROCE % Historical Data

The historical data trend for Ind-Swift Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ind-Swift Laboratories ROCE % Chart

Ind-Swift Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

5.31

7.30

7.00

11.85

52.44

Ind-Swift Laboratories Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															12.25	199.73	0.49	0.39	-0.38

Ind-Swift Laboratories ROCE % Calculation

Ind-Swift Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	6284.51	/	( ( (18240.64 - 3710.889)	+	(11651.063 - 2212.763) )	/ 2 )
	=	6284.51	/	( (14529.751	+	9438.3)	/ 2 )
	=	6284.51	/	11984.0255
	=	52.44 %

Ind-Swift Laboratories's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-38.692	/	( ( (11880.198 - 1643.714)	+	(0 - 0) )	/ 1 )
	=	-38.692	/	( ( 10236.484	+	0 )	/ 1 )
	=	-38.692	/	10236.484
	=	-0.38 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Ind-Swift Laboratories (BOM:532305) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ind-Swift Laboratories ROCE % Related Terms

Thank you for viewing the detailed overview of Ind-Swift Laboratories's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ind-Swift Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ind-Swift Laboratories Ltd (BOM:532305) » Definitions » ROCE %

Traded in Other Exchanges

INDSWFTLAB:India

Address

SCO 850, NAC, Shivalik Enclave, Manimajra, Chandigarh, PB, IND, 160101

Website

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd is engaged in the business of manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. It operates in a single segment namely, Bulk Drugs and Pharmaceuticals. Geographically, the company caters to both Indian and international markets, of which, maximum revenue is derived from outside India.

Ind-Swift Laboratories Headlines

No Headlines